Avalo Therapeutics (AVTX) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart

AVTX Stock Forecast

Avalo Therapeutics stock forecast is as follows: an average price target of $35.00 (represents a 292.82% upside from AVTX’s last price of $8.91) and a rating consensus of 'Hold', based on 4 wall street analysts offering a 1-year stock forecast.

AVTX Price Target

The average price target for Avalo Therapeutics (AVTX) is $35.00 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $35.00 to $35.00. This represents a potential 292.82% upside from AVTX's last price of $8.91.

AVTX Analyst Ratings

Hold

According to 4 Wall Street analysts, Avalo Therapeutics's rating consensus is 'Hold'. The analyst rating breakdown for AVTX stock is 0 'Strong Buy' (0.00%), 1 'Buy' (25.00%), 3 'Hold' (75.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Avalo Therapeutics Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Apr 16, 2024	Leland Gershell	Oppenheimer	$35.00	$15.24	129.66%	292.82%

The latest Avalo Therapeutics stock forecast, released on Apr 16, 2024 by Leland Gershell from Oppenheimer, set a price target of $35.00, which represents a 129.66% increase from the stock price at the time of the forecast ($15.24), and a 292.82% increase from AVTX last price ($8.91).

Avalo Therapeutics Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	1
Avg Price Target	-	-	$35.00
Last Closing Price	$8.91	$8.91	$8.91
Upside/Downside	-100.00%	-100.00%	292.82%

In the current month, the average price target of Avalo Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Avalo Therapeutics's last price of $8.91. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Oct 24, 2024	H.C. Wainwright		Neutral	Initialise
Aug 15, 2024	Oppenheimer	Outperform	Outperform	Hold
Apr 16, 2024	Oppenheimer		Outperform	Upgrade
Jun 27, 2023	Stephens	Equal-Weight	Equal-Weight	Hold
Jun 27, 2023	RBC Capital		Sector Perform	Downgrade
Feb 08, 2023	Jefferies		Underperform	Downgrade

Avalo Therapeutics's last stock rating was published by H.C. Wainwright on Oct 24, 2024. The company Initialise its AVTX rating from "null" to "Neutral".

Avalo Therapeutics Financial Forecast

Avalo Therapeutics Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 17	Jun 16
Revenue	-	-	-	-	-	-	-	-	-	$236.00K	$643.00K	$475.00K	$896.00K	$14.95M	$1.03M	$1.17M	$219.00K	$1.35M	$3.35M	$473.00K	$1.11M	$1.34M	$2.75M	$-8.72M	$5.61M	$4.45M	$5.41M	$384.21K	$650.49K
Avg Forecast	$241.62K	$243.07K	$244.54K	$246.02K	$300.00K	$300.00K	$300.00K	$300.00K	$300.00K	$1.00M	$1.00M	$1.00M	$3.61M	$1.26M	$1.19M	$645.50K	$1.02M	$1.12M	$333.33K	$539.33K	$1.50M	$2.25M	$1.84M	$4.95M	$5.34M	$4.71M	$3.17M	$748.19K	$698.08K
High Forecast	$241.62K	$243.07K	$244.54K	$246.02K	$300.00K	$300.00K	$300.00K	$300.00K	$300.00K	$1.00M	$1.00M	$1.00M	$3.61M	$1.26M	$1.19M	$645.50K	$1.02M	$1.12M	$333.33K	$539.33K	$1.50M	$2.25M	$1.84M	$4.95M	$5.34M	$4.71M	$3.81M	$897.83K	$837.70K
Low Forecast	$241.62K	$243.07K	$244.54K	$246.02K	$300.00K	$300.00K	$300.00K	$300.00K	$300.00K	$1.00M	$1.00M	$1.00M	$3.61M	$1.26M	$1.19M	$645.50K	$1.02M	$1.12M	$333.33K	$539.33K	$1.50M	$2.25M	$1.84M	$4.95M	$5.34M	$4.71M	$2.54M	$598.55K	$558.47K
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	9	15	16	8	11	7	11	7	17	15	12
Surprise %	-	-	-	-	-	-	-	-	-	0.24%	0.64%	0.47%	0.25%	11.88%	0.87%	1.82%	0.22%	1.21%	10.07%	0.88%	0.74%	0.59%	1.49%	-1.76%	1.05%	0.95%	1.71%	0.51%	0.93%

Avalo Therapeutics's average Quarter revenue forecast for Dec 23 based on 1 analysts is $300.00K, with a low forecast of $300.00K, and a high forecast of $300.00K. AVTX's average Quarter revenue forecast represents a 27.12% increase compared to the company's last Quarter revenue of $236.00K (Sep 23).

Avalo Therapeutics EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 17	Jun 16
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	9	15	16	8	11	7	11	7	17	15	12
EBITDA	-	-	-	-	-	-	-	-	-	$-3.75M	$-7.15M	$-8.82M	$-8.82M	$4.09M	$-11.80M	$-20.79M	$-20.10M	$-15.95M	$-17.09M	$-30.20M	$-13.03M	$-13.30M	$-22.81M	$2.91M	$-3.04M	$-5.25M	$-6.40M	$-2.01M	$-3.64M
Avg Forecast	$-241.62K	$-243.07K	$-244.54K	$-246.02K	$-300.00K	$-300.00K	$-300.00K	$-300.00K	$-300.00K	$-1.00M	$-1.00M	$-1.00M	$-3.61M	$-1.26M	$-1.19M	$-11.75M	$-1.02M	$-1.12M	$-333.33K	$-21.77M	$-1.50M	$-2.25M	$-31.95M	$-4.95M	$-5.34M	$-4.71M	$-7.35M	$-2.62M	$-3.76M
High Forecast	$-241.62K	$-243.07K	$-244.54K	$-246.02K	$-300.00K	$-300.00K	$-300.00K	$-300.00K	$-300.00K	$-1.00M	$-1.00M	$-1.00M	$-3.61M	$-1.26M	$-1.19M	$-9.40M	$-1.02M	$-1.12M	$-333.33K	$-17.42M	$-1.50M	$-2.25M	$-25.56M	$-4.95M	$-5.34M	$-4.71M	$-5.88M	$-2.09M	$-3.01M
Low Forecast	$-241.62K	$-243.07K	$-244.54K	$-246.02K	$-300.00K	$-300.00K	$-300.00K	$-300.00K	$-300.00K	$-1.00M	$-1.00M	$-1.00M	$-3.61M	$-1.26M	$-1.19M	$-14.10M	$-1.02M	$-1.12M	$-333.33K	$-26.13M	$-1.50M	$-2.25M	$-38.34M	$-4.95M	$-5.34M	$-4.71M	$-8.82M	$-3.14M	$-4.51M
Surprise %	-	-	-	-	-	-	-	-	-	3.75%	7.15%	8.82%	2.44%	-3.25%	9.94%	1.77%	19.75%	14.29%	51.26%	1.39%	8.69%	5.91%	0.71%	-0.59%	0.57%	1.12%	0.87%	0.77%	0.97%

1 analysts predict AVTX's average Quarter EBITDA for Dec 22 to be $-3.61M, with a high of $-3.61M and a low of $-3.61M. This is -188.17% lower than Avalo Therapeutics's previous annual EBITDA (Sep 22) of $4.09M.

Avalo Therapeutics Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 17	Jun 16
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	9	15	16	8	11	7	11	7	17	15	12
Net Income	-	-	-	-	-	-	-	-	-	$-5.23M	-	$-9.96M	$-9.81M	$3.19M	$-12.99M	$-22.05M	$-19.13M	$-17.39M	$-17.11M	$-30.68M	$-13.46M	$-13.28M	$-21.12M	$1.62M	$-4.02M	$-6.22M	$-7.45M	$-1.96M	$-3.52M
Avg Forecast	$-12.19M	$-12.40M	$-11.97M	$-12.19M	$-12.02M	$-12.83M	$-72.25M	$-12.73M	$-51.76M	$-2.85B	$-2.07B	$-2.51B	$-1.90B	$-1.61B	$-3.25B	$-11.20M	$-3.26B	$-3.70B	$-3.67B	$-22.11M	$-2.09B	$-2.31B	$-29.56M	$-2.57B	$-3.09B	$-3.23B	$-8.85M	$-2.62M	$-3.76M
High Forecast	$-12.19M	$-12.40M	$-11.97M	$-12.19M	$-11.70M	$-12.83M	$-72.25M	$-12.73M	$-51.76M	$-2.85B	$-2.07B	$-2.51B	$-1.90B	$-1.61B	$-3.25B	$-8.96M	$-3.26B	$-3.70B	$-3.67B	$-17.68M	$-2.09B	$-2.31B	$-23.65M	$-2.57B	$-3.09B	$-3.23B	$-7.08M	$-2.10M	$-3.01M
Low Forecast	$-12.19M	$-12.40M	$-11.97M	$-12.19M	$-12.24M	$-12.83M	$-72.25M	$-12.73M	$-51.76M	$-2.85B	$-2.07B	$-2.51B	$-1.90B	$-1.61B	$-3.25B	$-13.43M	$-3.26B	$-3.70B	$-3.67B	$-26.53M	$-2.09B	$-2.31B	$-35.48M	$-2.57B	$-3.09B	$-3.23B	$-10.62M	$-3.15M	$-4.52M
Surprise %	-	-	-	-	-	-	-	-	-	0.00%	-	0.00%	0.01%	-0.00%	0.00%	1.97%	0.01%	0.00%	0.00%	1.39%	0.01%	0.01%	0.71%	-0.00%	0.00%	0.00%	0.84%	0.75%	0.94%

Avalo Therapeutics's average Quarter net income forecast for Dec 22 is $-1.90B, with a range of $-1.90B to $-1.90B. AVTX's average Quarter net income forecast represents a -59560.86% decrease compared to the company's last Quarter net income of $3.19M (Sep 22).

Avalo Therapeutics SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 17	Jun 16
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	9	15	16	8	11	7	11	7	17	15	12
SG&A	-	-	-	-	-	-	-	-	-	$2.49M	$2.43M	$2.71M	$2.96M	$3.28M	$2.78M	$11.68M	$5.98M	$5.93M	$7.40M	$5.35M	$5.04M	$6.75M	$3.35M	$-4.85M	$5.31M	$5.32M	$5.83M	$1.33M	$1.64M
Avg Forecast	$760.51K	$765.10K	$769.72K	$774.37K	$944.28K	$944.28K	$944.28K	$944.28K	$944.28K	$3.15M	$3.15M	$3.15M	$11.36M	$3.96M	$3.73M	$2.03M	$3.20M	$3.51M	$1.05M	$1.70M	$4.72M	$7.08M	$5.80M	$15.58M	$16.79M	$14.82M	$9.98M	$2.36M	$2.20M
High Forecast	$760.51K	$765.10K	$769.72K	$774.37K	$944.28K	$944.28K	$944.28K	$944.28K	$944.28K	$3.15M	$3.15M	$3.15M	$11.36M	$3.96M	$3.73M	$2.03M	$3.20M	$3.51M	$1.05M	$1.70M	$4.72M	$7.08M	$5.80M	$15.58M	$16.79M	$14.82M	$11.98M	$2.83M	$2.64M
Low Forecast	$760.51K	$765.10K	$769.72K	$774.37K	$944.28K	$944.28K	$944.28K	$944.28K	$944.28K	$3.15M	$3.15M	$3.15M	$11.36M	$3.96M	$3.73M	$2.03M	$3.20M	$3.51M	$1.05M	$1.70M	$4.72M	$7.08M	$5.80M	$15.58M	$16.79M	$14.82M	$7.98M	$1.88M	$1.76M
Surprise %	-	-	-	-	-	-	-	-	-	0.79%	0.77%	0.86%	0.26%	0.83%	0.75%	5.75%	1.87%	1.69%	7.06%	3.15%	1.07%	0.95%	0.58%	-0.31%	0.32%	0.36%	0.58%	0.56%	0.74%

Avalo Therapeutics's average Quarter SG&A projection for Dec 23 is $944.28K, based on 1 Wall Street analysts, with a range of $944.28K to $944.28K. The forecast indicates a -62.08% fall compared to AVTX last annual SG&A of $2.49M (Sep 23).

Avalo Therapeutics EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 17	Jun 16
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	9	15	16	8	11	7	11	7	17	15	12
EPS	-	-	-	-	-	-	-	-	-	$-0.11	$-0.59	$-0.85	$-1.16	$0.34	$-1.38	$-2.35	$-2.28	$-2.04	$-2.16	$-3.84	$-2.04	$-2.28	$-4.08	$0.35	$-0.84	$-1.32	$-1.56	$-2.28	$-4.92
Avg Forecast	$-1.13	$-1.15	$-1.11	$-1.13	$-1.11	$-1.19	$-6.70	$-1.18	$-4.80	$-264.00	$-192.00	$-232.80	$-176.00	$-210.60	$-424.80	$-360.00	$-426.24	$-483.84	$-480.00	$-480.00	$-273.60	$-302.40	$-297.60	$-336.00	$-403.20	$-422.40	$-2.28	$-5.94	$-5.64
High Forecast	$-1.13	$-1.15	$-1.11	$-1.13	$-1.09	$-1.19	$-6.70	$-1.18	$-4.80	$-264.00	$-192.00	$-232.80	$-176.00	$-210.60	$-424.80	$-360.00	$-426.24	$-483.84	$-480.00	$-480.00	$-273.60	$-302.40	$-297.60	$-336.00	$-403.20	$-422.40	$-1.82	$-4.75	$-4.51
Low Forecast	$-1.13	$-1.15	$-1.11	$-1.13	$-1.13	$-1.19	$-6.70	$-1.18	$-4.80	$-264.00	$-192.00	$-232.80	$-176.00	$-210.60	$-424.80	$-360.00	$-426.24	$-483.84	$-480.00	$-480.00	$-273.60	$-302.40	$-297.60	$-336.00	$-403.20	$-422.40	$-2.74	$-7.13	$-6.77
Surprise %	-	-	-	-	-	-	-	-	-	0.00%	0.00%	0.00%	0.01%	-0.00%	0.00%	0.01%	0.01%	0.00%	0.00%	0.01%	0.01%	0.01%	0.01%	-0.00%	0.00%	0.00%	0.68%	0.38%	0.87%

According to 1 Wall Street analysts, Avalo Therapeutics's projected average Quarter EPS for Dec 22 is $-176.00, with a low estimate of $-176.00 and a high estimate of $-176.00. This represents a -51864.71% decrease compared to AVTX previous annual EPS of $0.34 (Sep 22).

Avalo Therapeutics Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
BNOX	Bionomics	$0.27	$6.00	2122.22%	Buy
ALXO	ALX Oncology	$1.79	$24.50	1268.72%	Buy
MOLN	Molecular Partners	$5.25	$29.00	452.38%	Buy
AVTE	Aerovate Therapeutics	$2.56	$13.00	407.81%	Hold
CCCC	C4 Therapeutics	$4.05	$20.00	393.83%	Buy
ANEB	Anebulo Pharmaceuticals	$1.31	$6.00	358.02%	Buy
IPSC	Century Therapeutics	$1.17	$5.00	327.35%	Buy
PMVP	PMV Pharmaceuticals	$1.52	$6.00	294.74%	Buy
AVTX	Avalo Therapeutics	$9.38	$35.00	273.13%	Hold
GPCR	Structure Therapeutics	$31.48	$99.00	214.49%	Buy
ACRV	Acrivon Therapeutics	$7.21	$22.50	212.07%	Buy
ANAB	AnaptysBio	$15.99	$49.83	211.63%	Buy
CGEM	Cullinan Oncology	$11.49	$34.00	195.91%	Buy
MLYS	Mineralys Therapeutics	$12.35	$30.00	142.91%	Buy
BNTC	Benitec Biopharma	$12.77	$20.33	59.20%	Buy
EWTX	Edgewise Therapeutics	$30.17	$46.25	53.30%	Buy
ACLX	Arcellx	$82.03	$111.60	36.05%	Buy

AVTX Forecast FAQ

Is Avalo Therapeutics a good buy?

No, according to 4 Wall Street analysts, Avalo Therapeutics (AVTX) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 25.00% of AVTX's total ratings.

What is AVTX's price target?

Avalo Therapeutics (AVTX) average price target is $35 with a range of $35 to $35, implying a 292.82% from its last price of $8.91. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Avalo Therapeutics stock go up soon?

According to Wall Street analysts' prediction for AVTX stock, the company can go up by 292.82% (from the last price of $8.91 to the average price target of $35), up by 292.82% based on the highest stock price target, and up by 292.82% based on the lowest stock price target.

Can Avalo Therapeutics stock reach $13?

AVTX's average twelve months analyst stock price target of $35 supports the claim that Avalo Therapeutics can reach $13 in the near future.

What are Avalo Therapeutics's analysts' financial forecasts?

Avalo Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $1.2M (high $1.2M, low $1.2M), average EBITDA is $-1.2M (high $-1.2M, low $-1.2M), average net income is $-110M (high $-110M, low $-110M), average SG&A $3.78M (high $3.78M, low $3.78M), and average EPS is $-10.185 (high $-10.155, low $-10.205). AVTX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $975.25K (high $975.25K, low $975.25K), average EBITDA is $-975K (high $-975K, low $-975K), average net income is $-48.744M (high $-48.744M, low $-48.744M), average SG&A $3.07M (high $3.07M, low $3.07M), and average EPS is $-4.52 (high $-4.52, low $-4.52).

Did the AVTX's actual financial results beat the analysts' financial forecasts?

Based on Avalo Therapeutics's last annual report (Dec 2023), the company's revenue was $1.41M, which missed the average analysts forecast of $3.3M by -57.33%. Apple's EBITDA was $-27.867M, beating the average prediction of $-3.3M by 744.45%. The company's net income was $-31.544M, missing the average estimation of $-7.48B by -99.58%. Apple's SG&A was $10.3M, missing the average forecast of $10.39M by -0.84%. Lastly, the company's EPS was $-114, missing the average prediction of $-694 by -83.56%. In terms of the last quarterly report (Sep 2023), Avalo Therapeutics's revenue was $236K, missing the average analysts' forecast of $1M by -76.40%. The company's EBITDA was $-3.75M, beating the average prediction of $-1M by 275.00%. Avalo Therapeutics's net income was $-5.228M, missing the average estimation of $-2.847B by -99.82%. The company's SG&A was $2.49M, missing the average forecast of $3.15M by -20.89%. Lastly, the company's EPS was $-0.11, missing the average prediction of $-264 by -99.96%